-
Publication Venue For
-
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.
2020
-
T-lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classification..
190:e307-e312.
2020
-
The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency.
2020
-
Acute myeloid leukaemia with maturation demonstrates persistent disease with prominent megakaryoblastic differentiation 16 days following induction chemotherapy: an intra-myeloid lineage switch mediated by chemotherapy-induced clonal selection..
189:e64-e67.
2020
-
Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.
2020
-
Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease..
188:e64-e67.
2020
-
Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma..
188:e33-e36.
2020
-
Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry..
187:602-614.
2019
-
Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al..
186:637.
2019
-
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)..
185:53-64.
2019
-
Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study..
184:647-650.
2019
-
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia..
184:605-615.
2019
-
Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling..
183:747-754.
2018
-
"Faggot" neutrophils in acute promyelocytic leukaemia with ongoing tretinoin therapy..
183:169.
2018
-
Understanding patterns and correlates of daily pain using the Sickle cell disease Mobile Application to Record Symptoms via Technology (SMART)..
183:306-308.
2018
-
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma..
178:434-441.
2017
-
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results..
178:561-570.
2017
-
Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?.
176:337-340.
2017
-
Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke..
176:300-308.
2017
-
Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion..
175:935-948.
2016
-
Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists..
174:610-623.
2016
-
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study..
172:384-391.
2016
-
Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial..
172:122-130.
2016
-
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study..
169:534-543.
2015
-
Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia..
168:405-412.
2015
-
Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex® system..
167:281-285.
2014
-
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS..
167:62-68.
2014
-
Suspicious mammographic masses in the breast: splenosis in an unusual body site due to a remote ballistic trauma..
167:148.
2014
-
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes..
166:352-359.
2014
-
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002..
165:102-111.
2014
-
Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement..
162:648-656.
2013
-
'Hypopyon' in the anterior chamber: unilateral ocular relapse of acute myeloid leukaemia in a 2-year-old girl..
162:293.
2013
-
Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR)..
161:896-898.
2013
-
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis..
161:508-516.
2013
-
Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes..
159:572-576.
2012
-
Myelomatous meningeal infiltration detected by magnetic resonance imaging..
159:122.
2012
-
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia..
158:581-588.
2012
-
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo..
155:426-437.
2011
-
MYH9 and APOL1 are both associated with sickle cell disease nephropathy..
155:386-394.
2011
-
ADA-SCID with 'WAZA-ARI' mutations that synergistically abolished ADA protein stability..
153:675-676.
2011
-
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)..
153:504-507.
2011
-
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial..
152:771-776.
2011
-
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome..
152:284-294.
2011
-
Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients..
152:72-80.
2011
-
Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families..
151:152-158.
2010
-
Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience..
151:103-106.
2010
-
Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions..
148:356-372.
2010
-
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia..
148:48-58.
2010
-
Oligoclonal TRBV gene usage among CD8(+) T cells in monoclonal B lymphocytosis and CLL..
145:535-537.
2009
-
Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean..
145:266-267.
2009
-
Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway..
142:671-673.
2008
-
The non-haematopoietic biological effects of erythropoietin..
141:14-31.
2008
-
beta(2)-Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion..
141:105-108.
2008
-
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B..
140:313-319.
2008